Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck

Abstract
Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy.